Clinical Trials

Prostatic Neoplasms

NCT03419234 2026-03-12

Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

223 enrolled 14 charts

Prostatic Neoplasms

NCT02703623 2026-03-06

Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

196 enrolled

Prostatic Neoplasms

NCT04748042 2026-03-06

Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)

21 enrolled

Prostatic Neoplasms

NCT06632977 2026-03-04

PREDICT

474 enrolled

Prostatic Neoplasms

NCT07005154 2026-03-03

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

218 enrolled

Prostatic Neoplasms

NCT01314118 2026-02-24

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

131 enrolled 12 charts

Prostatic Neoplasms

NCT01786265 2026-02-20

Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer

310 enrolled

Prostatic Neoplasms

NCT04947254 2026-02-19

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

200 enrolled

Prostatic Neoplasms

NCT06616597 2026-02-19

Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer

58 enrolled

Adenocarcinoma, Prostatic Neoplasms

NCT05137262 2026-02-18

A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder

12 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03902951 2026-02-05

Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer

28 enrolled

Prostatic Neoplasms

NCT04734730 2026-01-28

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

70 enrolled

Prostatic Neoplasms

NCT03565835 2026-01-26

Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer

31 enrolled 11 charts

Prostatic Neoplasms

NCT04267887 2026-01-20

Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer

7 enrolled

Prostatic Neoplasms

NCT01995058 2026-01-08

Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC

Phase 2 Terminated

54 enrolled 11 charts

Prostatic Neoplasms

NCT02949284 2026-01-07

Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

90 enrolled

Stage II Prostate Adenocarcinoma

NCT05689021 2026-01-07

CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

8 enrolled

Prostatic Neoplasms

NCT06384222 2025-12-30

Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone

32 enrolled

Prostatic Neoplasms

NCT06378866 2025-12-26

DIVINE

532 enrolled

Prostatic Neoplasms

NCT03431350 2025-12-23

QUEST

136 enrolled 29 charts

Prostatic Neoplasms, Castration-Resistant

NCT04175431 2025-12-18

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

100 enrolled

Prostate Adenocarcinoma

NCT02960022 2025-12-17

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

900 enrolled

Prostatic Neoplasms

NCT03833921 2025-12-11

APRE

130 enrolled

Prostatic Neoplasms

NCT03007732 2025-12-05

Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT

23 enrolled 14 charts

Prostatic Neoplasms

NCT03436654 2025-11-28

Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma

102 enrolled

Prostatic Neoplasms

NCT06369610 2025-11-14

Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer

110 enrolled

Oligometastatic Prostate Carcinoma

NCT03012321 2025-10-21

Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

70 enrolled

Prostatic Neoplasms

NCT06392841 2025-10-20

HARMONY

Phase 2 Withdrawn

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT03821792 2025-10-10

Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer

60 enrolled

Prostatic Neoplasms

NCT05588609 2025-09-18

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Phase 2 Terminated

13 enrolled

GenitourinaryThoracic

NSCLC Harboring NRG1 Fusion

NCT03098836 2025-09-12

PANTHER

93 enrolled 17 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT03458247 2025-09-05

OPTIMABI

94 enrolled

Prostatic Neoplasms

NCT03298087 2025-08-01

Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer

28 enrolled 10 charts

Newly Diagnosed Oligometastatic Prostate Cancer

NCT02903368 2025-06-13

Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy

118 enrolled 23 charts

Prostatic Neoplasms

NCT06971211 2025-05-14

PARTOM

40 enrolled

Prostatic Neoplasms

NCT06212583 2025-05-01

KNIGHTS

88 enrolled

Prostatic Neoplasms

NCT05593497 2025-04-16

SNARE

30 enrolled

Prostatic Neoplasms

NCT02025010 2025-04-15

Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer

60 enrolled 17 charts